SciSight Ecosystem
WoS SCIE Q3Scopus Q2SCImago #11,927CAS 4区Hybrid

Cancer Biotherapy and Radiopharmaceuticals

Abbreviation (ISO):CANCER BIOTHER. RADIOPHARM
Country: United States•WoS SCIE Quartile: Q3•Scopus SJR: 0.498•SCImago Rank: #11,927•Identifier (ISSN):1084-9785(Print)/1557-8852(Online)•Articles / Year: 100•Estimated Publication Fee (APC): $3,010 USD
Clarivate IF (2026)Q3
1.7
↓ -0.4

Leading citation impact metric from Clarivate Journal Citation Reports

JCR Release Date: 2026-06-17
H-Index (2021)
55

55 papers with at least that number of citations each

WoS: SCIE / JCRQ3
Self-Citation Rate0%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
100articles/year
7.65% Gold OA•100% Original Research

State Council for Professorship (HĐGSNN) Scoring

Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)

1.50pts
Latest Max Score
Estimated (Dec 26)
Scoring Basis: WoS Q3(IF: 1.7)

HĐGSNN Score History

By article publication year
YearMax ScoreEvaluation DetailsSource
20261.50đ
WoS Q3(IF: 1.7)
🔵 Computed
20251.50đ
WoS Q3(IF: 2.1)
🔵 Computed
20241.50đ
WoS Q3(IF: 2.4)
🔵 Computed
20231.50đ
WoS Q3(IF: 3.4)
🔵 Computed
20221.50đ
WoS Q3(IF: 3.632)
🔵 Computed
20211.50đ
WoS Q3(IF: 3.099)
🔵 Computed
20201.50đ
WoS Q3(IF: 2.314)
🔵 Computed
20191.50đ
WoS Q3(IF: 1.894)
🔵 Computed
20181.50đ
WoS Q3(IF: 1.682)
🔵 Computed

Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.

Aims & Scope

Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.

Topics Covered (Recognized by AI)
Medicine97.5%Biology91.5%Genetics86.2%Internal medicine82.3%Chemistry70.3%Biochemistry61.2%Cancer research50.3%Cancer47.9%Immunology44.4%Pathology38.5%Surgery31.9%In vitro30.5%Physics30%Gene28.9%Radiology27.3%Nuclear medicine26.9%Oncology22.3%Cell culture21.7%Organic chemistry21.6%Biotechnology20.9%Apoptosis20.6%In vivo20.4%

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #11,927Scopus Q2SCImago Profile
Scopus Coverage:1996-2026
Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyMedicinePharmacology, Toxicology and Pharmaceutics
Scopus Citation Rank (SJR)Q2
0.498

Weighted prestige citation metric per document indexed in the Scopus database.

Tứ phân vị: Scopus Q2
Scopus H-Index (2025)
74

Measures cumulative publication volume and citation impact.

Scopus Database Indexed (2025)
Citations / Doc (2 years)
1.94

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,010 USD

Estimated Article Processing Charge for Open Access publication.

Chi phí ước tính / bài báo

Scopus 3-Year Publication & Citation Window

3-Year Citations546
3-Year Documents259
Citable Documents254

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate42.0%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Radiology, Nuclear Medicine and ImagingQ2
Medicine (miscellaneous)Q3
OncologyQ3
PharmacologyQ3
Cancer ResearchQ4

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
4区 (Zone 4)Medicine
Minor Category (Specific Field):
4区ONCOLOGY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Publisher Review Speed
Updating
Average time to first editorial decision
Online Publication Speed
Updating
Time from acceptance to online publication
Official Acceptance Rate
Updating
Manuscript acceptance rate confirmed by the publisher
Open Access Model
Hybrid
OA publishing option or traditional subscription
Publisher
Mary Ann Liebert Inc.
Publication Language
English
Frequency
Bimonthly
Founding Year
1996
Editorial Address
MARY ANN LIEBERT INC, 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, USA, NY, 10801
Indexing & Databases
SCIEScopusPubMed

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
CategoryIndexRankQuartile
MEDICINE, RESEARCH & EXPERIMENTAL
JCRSCIE
141/191Q3
ONCOLOGY
JCRSCIE
273/333Q4
PHARMACOLOGY & PHARMACY
JCRSCIE
267/356Q3
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
JCRSCIE
137/217Q3
MEDICINE, RESEARCH & EXPERIMENTAL
JCISCIE
123/191Q3
ONCOLOGY
JCISCIE
235/333Q3
PHARMACOLOGY & PHARMACY
JCISCIE
248/356Q3
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
JCISCIE
136/217Q3

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
YearImpact FactorArticles / YearTotal Citations
2026—627
20252.18880
20242.468139
20233.437133
20223.63251343
20213.099121925
20202.3142193,873
20191.894851,568
20181.682781,197
2017—50935
2016—50961
2015—55926
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Impact Factor Trend (2018–2024)

Clarivate IF trend for Cancer Biotherapy and Radiopharmaceuticals

WoS Q3
1245201820192020202120222023202420252.10
Annual Impact Factor Metric
2025:2.1

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 0%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 3b06ce95-c5bf-46f2-98ad-7be302b18c62
Database Updated: 2026-09-28